Selective toxicity of rose bengal to ovarian cancer cells in vitro

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 4, Issue 2, 2012, Pages 99-107

  Koevary, Steven B ^a,b  

^a NEW ENGLAND COLLEGE OF OPTOMETRY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; BRCA1; MTT assay; Ovarian cancer; Reactive oxygen species; Rose bengal

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CARBOPLATIN; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; ROSE BENGAL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TUMOR; OVARY CANCER; TUMOR CELL;

EID: 84863908310     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Argueso P, Tisdale A, Spurr-Michaud S, Sumiyoshi M and Gipson IK. Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest Ophthalmol Vis Sci 2006; 47: 113-119.
2. Khan-Lim D and Berry M. Still confused about rose bengal? Curr Eye Res 2004; 29: 311-317.
3. Kishen A, Upadya M, Tegos GP and Hamblin MR. Efflux pump inhibitor potentiates antimicrobial photodynamic inactivation of Enterococcus faecalis biofilm. Photochem Photobiol 2010; 86: 1343-1349.
4. Kato H, Komagoe K, Inoue T and Katsu T. In situ monitoring of photodynamic inactivation of the membrane functions of bacteria using electrochemical sensors. Anal Sci 2010; 26: 1019-1021.
5. Panzarini E, Tenuzzo B and Dini L. Photodynamic therapy-induced apoptosis of HeLa cells. Ann N Y Acad Sci 2009; 1171: 617-626.
6. Dini L, Inguscio V, Tenuzzo B and Panzarini E. Rose bengal acetate photodynamic therapyinduced autophagy. Cancer Biol Ther 2010; 10: 1048-1055.
7. Nonaka M, Yamamoto M, Yoshino S, Umemura S, Sasaki K and Fukushima T. Sonodynamic therapy consisting of focused ultrasound and a photosensitizer causes a selective antitumor effect in a rat intracranial glioma model. Anticancer Res 2009; 29: 943-950.
8. Sugita N, Iwase Y, Yumita N, Ikeda T and Umemura S. Sonodynamically induced cell damage using rose bengal derivative. Anticancer Res 2010; 30: 3361-3366.
9. Sugita N, Kawabata K, Sasaki K, Sakata I and Umemura S. Synthesis of amphiphilic derivatives of rose bengal and their tumor accumulation. Bioconjug Chem 2007; 18: 866-873.
10. Foote MC, Burmeister BH, Thomas J and Mark Smithers B. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 2010; 20: 48-51.
11. Thompson JF, Hersey P and Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008; 18: 405-411.
12. Agarwala S, Thompson J, Smithers BM, Ross MI, Coventry BJ, Minor DR, Scoggins C and Wachter EA. Chemoablation of metastatic melanoma with intralesional PV-10. Pigment Cell Melanoma Res 2010; 23: 891.
13. Agarwala S. PV-10, aka Rose Bengal: Intralesional therapy for metastatic melanoma. The Melanoma Letter 2012; 30: 6-9.
14. American Cancer Society: Cancer facts & figures 2008, American Cancer Society Atlanta, Ga. 2008.
15. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/ posted to the SEER web site, 2007.
16. Suto A, Kubota T, Shimoyama Y, Ishibiki K and Abe O. MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 1989; 42: 28-32.
17. Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ, Zhou L, Zhang J and Liu XW. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999; 53: 77-85.
18. Gonzalez VM, Fuertes MA, Alonso C and Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-663.
19. Rogalska A, Gajek A, Szwed M, Jozwiak Z and Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol In Vitro 2011; 25: 1712-1720.
20. Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW and Yang HO. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 2004; 91: 1043-1052.
21. Ye K. PARP inhibitor tilts cell death from necrosis to apoptosis in cancer cells. Cancer Biol Ther 2008; 7: 942-944.
22. Yang YI, Kim JH, Lee KT and Choi JH. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol Oncol 2011; 123: 588-596.
23. Nguyen H and Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol 2011; 27: 830-836.
24. Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS and Moore RG. Antiangiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol 2012; 40: 227-235.
25. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-507.
26. Lessene G, Czabotar PE and Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
27. Izeradjene K, Douglas L, Tillman DM, Delaney AB and Houghton JA. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligandresistant human colon carcinoma cell lines. Cancer Res 2005; 65: 7436-7445.
28. Kannan K, Holcombe RF, Jain SK, Alvarez-Hernandez X, Chervenak R, Wolf RE and Glass J. Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line. Mol Cell Biochem 2000; 205: 53-66.
29. Kannan K and Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7: 153-163.
30. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10: 1881-1896.
31. Cerutti PA. Prooxidant states and tumor promotion. Science 1985; 227: 375-381.
32. Weinberg F and Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009; 66: 3663-3673.
33. Mastrangelo MJ, Bellet RE, Berkelhammer J and Clark WH Jr. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 1975; 36: 1305-1308.
34. Johansson A, Hamzah J, Payne CJ and Ganss R. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 2012; 109: 7841-7846.
35. Jia SF, Duan X, Worth LL, Guan H and Kleinerman ES. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. Cancer Gene Ther 2006; 13: 948-957.
36. Dubrot J, Palazon A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervas-Stubbs S and Melero I. Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer 2011; 128: 105-118.
37. Abdel-Motal UM, Wigglesworth K and Galili U. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 2009; 58: 1545-1556.
38. Mousavi H, Zhang X, Gillespie S, Wachter E, Hersey P. Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 2006; 16: S8.
39. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
40. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W and Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004; 191: 1598-1605.
41. Dranoff G. The therapeutic implications of intratumoral regulatory T cells. Clin Cancer Res 2005; 11: 8226-8229.
42. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S and Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14: 3372-3379.
43. Bosmuller H, Haitchi-Petnehazy S, Webersinke G, Marschon R, Roithmeier F, Stummvoll W, Fehm T, Klier-Richter M, Bonzheim I, Staebler A and Fend F. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinumbased therapy. Virchows Arch 2011; 459: 183-191.